@theinnovation.bsky.socialBy combining MRI with NIR-II fluorescence, this dual-modal platform links preoperative localization to intraoperative guidance, with encouraging evidence from mouse models and fresh human tissue specimens.
doi.org/10.59717/j.x...
#medical #NonSmallCellLungCancer
@cedarssinaicancer.bsky.socialDo you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
@cedarssinaicancer.bsky.socialDo you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
@theinnovation.bsky.socialNew in The Innovation Drug Discovery!
Limertinib adopts a combination of mutation selectivity and irreversible inhibition design, which can provide a new option for the treatment of EGFR mutant lung cancer.
doi.org/10.59717/j.x...
#NonSmallCellLungCancer #targetedtheraphy
@pulmonologyadvisor.bsky.socialIn patients with #NonSmallCellLungCancer, active imaging surveillance may improve overall survival following definitive treatment. #PulmSky #OncSky
@4040rec.bsky.social@cedarssinaicancer.bsky.socialDo you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.
@cedarssinaicancer.bsky.socialDo you have EGFR-Mutated #NonSmallCellLungCancer and are considering treatment? You may be eligible for the #Copernicus clinical trial. Follow the link below or call (424)-312-0745 to learn more.